Clinical Research: Available Trials

Picture
CMOH offers clinical trials through US Oncology Research, one of the largest community-based research programs in the U.S., with over 60 research sites. US Oncology Research has enrolled over 80,000 patients in clinical trials and played a role in nearly 100 FDA-approved cancer therapies.
Throughout the last century, the medical community has witnessed dramatic changes in the methods of diagnosis and treatment of cancer. Cancer research is no longer conducted exclusively at large university cancer centers or major metropolitan hospitals. CMOH's physicians have embraced clinical cancer research as a critical component of community-based oncology care. Through a partnership with The US Oncology Network.  You do not have to leave the area to receive premier cancer care.

 If you are interested in learning more about our research program, please contact (215) 658-7240. 

BREAST:
  • 18247 elacestrant monotherapy vs. standard of care for the treatment of patients with er+/her2- advanced breast cancer following cdk4/6 inhibitor therapy: a phase 3 randomized, open-label, active-controlled, multicenter trial(emerald)(rad1901-308)
  • 14059 phase ii trial of ibrutinib plus trastuzumab in her2-amplified metastatic breast cancer
  • 17079 mammaprint, blueprint, and full-genome data linked with clinical data to evaluate new gene expression profiles: an adaptable registry (flex registry)
  • 19054 randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (t-dm1) for subjects with unresectable locally-advanced or metastatic her2+ breast cancer (her2climb-02)(sgntuc-016)
 
CHOLANGIO:
  • 18264 a phase 3 multicenter, open-label, randomized, controlled study of oral infigratinib versus gemcitabine with cisplatin in subjects with advanced/metastatic or inoperable cholangiocarcinoma with fgfr2 gene fusions/translocations: the proof trial (qbgj398-301)
 
CLL:
  • 18263 a phase 2, multicenter, single-arm study of zanubrutinib (bgb-3111) in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma intolerant of prior treatment with ibrutinib (bgb-3111-215)
  • 19084 a single-arm, expanded access study of zanubrutinib (bgb-3111) in patients with relapsed/refractory (r/r) mantle cell lymphona (bgb-3111-216)
  • 19182 a prospective, open-label, multicenter randomized phase iii trial to compare the efficacy and safety of a combined regimen of obinutuzumab and venetoclax versus fludarabine, cyclophosphamide and rituximab (fcr)/ bendamustine and rituximab (br) in fit patients with previously untreated chronic lymphocytic leukemia (cll) without del (17p) or tp53 mutation (co41685)
 
HODGKINS:
  • 11282 (sgn35-015) a phase 2 open-label study of brentuximab vedotin in front-line therapy of hodgkin lymphoma (hl) and cd30-expressing peripheral t-cell lymphoma (ptcl) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
  • 18013 sgn35-027: multiple part clinical trial of brentuximab vedotin (including nivolumab) in classical hodgkin lymphoma subject
 
LUNG:
  • 19018 a randomized phase 3 study of sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous non-small cell lung cancer with disease progression on or after platinum-based chemotherapy and checkpoint inhibitor therapy (sapphire)
  • 20142 efficacy, safety of tecentriq combination with cabometyx compared with docetaxel monotherapy in patients with metastatic non-small cell lung cancer previously treated with an immune checkpoint inhibitor and platinum-based chemotherapy
  • 18129 brigatinib-3001- a phase 3 randomized open-label study of brigatinib (alunbrig®)versus alectinib (alecensa®) in advanced anaplastic lymphoma kinase-positive non–small-cell lung cancer patients who have progressed on crizotinib (xalkori®) -alk+
  • 19208 a randomized, open-label, phase 3 study of pralsetinib versus standard of care for first line treatment of ret fusion-positive, metastatic non-small cell lung cancer (blu-667-2303)
  • 19020 a randomized, double-blind, phase 3 study of pemetrexed + platinum chemotherapy with or without pembrolizumab (mk-3475) in tki-resistant egfr-mutated tumors in metastatic non-squamous non-small cell lung cancer (nsclc) participants (keynote-789; mk-3475-789)

MYELOFIBROSIS:
  • 19171 a randomized, controlled phase 3 study of pacritinib versus physician's choice in patients with primary myelofibrosis, post polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis with severe thrombocytopenia (platelets counts <50,000/µl) (pac203)

PROSTATE:
  • 16238 triton3: a multicenter, randomized, open-label phase 3 study of rucaparib versus physician's choice of therapy for patients with metastatic castration-resistant prostate cancer associated with homologous recombination deficiency (co-338-063)
  • 18103 a phase 3 randomized, placebo-controlled, double-blind study of niraparib in combination with abiraterone acetate and prednisone versus abiraterone acetate and prednisone for treatment of subjects with metastatic prostate cancer(64091742pcr3001)
  • 19146 - star ph1b/2 nirap combo tx for mcrpca phase 1b-2 study of niraparib combination therapies for the treatment of metastatic castration-resistant prostate cancer (pcr2002 quest) (64091742pcr2002)

SOLID TUMOR:
  • 19079 (incb 54828-207) a phase 2, open-label, single-arm, multicenter study to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically
  • unresectable solid tumor malignancies harboring activating fgfr mutations or translocations (fight-207)
  • 19092 a phase 2 study of erdafitinib in subjects with advanced solid tumors and fgfr gene alterations (42756493can2002)
  • 18164 a phase 1/2 study of the highly-selective ret inhibitor, blu-667, in patients with thyroid cancer, non-small cell lung cancer (nsclc) and other advanced solid tumors (blu-667-1101)
  • 20186 tumor-agnostic precision immuno-oncology and somatic targeting rational for you (tapistry) phase ii platform
 
UROTHELIAL:
  • 19032 biomarker study to identify subjects with advanced urothelial cancer and fibroblast growth factor receptor gene aberrations (42756493blc0002)
  • 17133 (42756493blc3001) a phase 3 study of erdafitinib compared with vinflunine or docetaxel or pembrolizumab in subjects with advanced urothelial cancer and selected fgfr gene aberrations (thor)
  • 19094 qbgj398-302: phase 3, multicenter, double-blind, randomized, placebo-controlled trial of infigratinib for the adjuvant treatment of subjects with invasive urothelial carcinoma with susceptible fgfr3 genetic alterations (proof302)
  • 20172  star ph 2 asg-22ce urothelial cancer, a study of enfortumab vedotin (asg-22ce) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (sgn22e-002)

Learn more.

Take action.

"At CMOH, we are able to combine a personal touch with high quality treatment. This is a friendly environment. Our physicians, nurses and staff are all very approachable."  
- Maureen Lowry, MHA, BSN, RN, OCN